ORIC Pharmaceuticals, Inc.
ORIC
$9.85
$0.232.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.48% | 12.82% | 12.55% | 15.05% | 13.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.62% | 28.51% | 28.99% | 32.80% | 33.84% |
| Operating Income | -19.62% | -28.51% | -28.99% | -32.80% | -33.84% |
| Income Before Tax | -23.89% | -30.56% | -26.96% | -28.60% | -19.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.89% | -30.56% | -26.96% | -28.60% | -19.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.89% | -30.56% | -26.96% | -28.60% | -19.68% |
| EBIT | -19.62% | -28.51% | -28.99% | -32.80% | -33.84% |
| EBITDA | -19.68% | -28.68% | -29.19% | -33.08% | -34.12% |
| EPS Basic | -7.32% | -3.87% | 7.15% | 9.42% | 19.16% |
| Normalized Basic EPS | -7.33% | -3.88% | 7.14% | 9.42% | 14.20% |
| EPS Diluted | -7.32% | -3.87% | 7.15% | 9.42% | 19.16% |
| Normalized Diluted EPS | -7.33% | -3.88% | 7.14% | 9.42% | 14.20% |
| Average Basic Shares Outstanding | 14.97% | 24.01% | 35.64% | 41.13% | 48.18% |
| Average Diluted Shares Outstanding | 14.97% | 24.01% | 35.64% | 41.13% | 48.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |